Raymond James Financial Portfolio holdings
Raymond James Financial, founded in 1962 by Robert James and headquartered in St. Petersburg, Florida, is a diversified financial services firm managing over $1.5 trillion in client assets as of late 2024, primarily focused on wealth management, investment banking, and brokerage services. Known for its advisor-centric model, the firm supports over 8,900 financial advisors across the U.S., Canada, and the UK, offering personalized financial planning, retirement solutions, and investment products to individuals, small businesses, and institutions. Its investment banking arm specializes in middle-market mergers, acquisitions, and equity offerings, while its Raymond James Bank provides lending and deposit services. With a reputation for a conservative, client-first culture and steady growth—including a notable acquisition of TriState Capital in 2022—Raymond James stands out as a resilient, relationship-driven player in the financial industry.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Vanguard S&P 500 ETF
VOO
|
+$962M |
| 2 |
AbbVie
ABBV
|
+$512M |
| 3 |
Bank of America
BAC
|
+$172M |
| 4 |
TJX Companies
TJX
|
+$157M |
| 5 |
GE Vernova
GEV
|
+$156M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Merck
MRK
|
+$636M |
| 2 |
iShares Core US Aggregate Bond ETF
AGG
|
+$388M |
| 3 |
Palantir
PLTR
|
+$253M |
| 4 |
Applovin
APP
|
+$236M |
| 5 |
iShares 7-10 Year Treasury Bond ETF
IEF
|
+$212M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Miscellaneous | 39.84% |
| 2 | Technology | 16.54% |
| 3 | Financials | 9.27% |
| 4 | Industrials | 6.9% |
| 5 | Healthcare | 6.27% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
2826
ACV Auctions
ACVA
$1.77B
| $2.73M | ﹤0.01% |
168,269
-1,734
| -1% | -$27K |
2024 Q4
2 quarters
|
|
2827
RH
RH
$2.28B
| $2.72M | ﹤0.01% |
14,411
-120,631
| -89% | -$22.4M |
2024 Q4
2 quarters
|
|
2828
First Trust Exchange-Traded Fund VIII First Trust Income Opportunities ETF
FCEF
$80.8M
| $2.72M | ﹤0.01% |
121,098
+3,641
| +3% | +$77.8K |
2024 Q4
2 quarters
|
|
|
EMBJ
2829
Embraer S.A. ADS
EMBJ
$13.2B
| $2.72M | ﹤0.01% |
47,712
+10,303
| +28% | +$487K |
2024 Q4
2 quarters
|
|
2830
Essent Group
ESNT
$5.29B
| $2.71M | ﹤0.01% |
44,704
+49
| +0.1% | +$2.82K |
2024 Q4
2 quarters
|
|
2831
iShares US Healthcare Providers ETF
IHF
$1.34B
| $2.71M | ﹤0.01% |
55,731
+12,174
| +28% | +$600K |
2024 Q4
2 quarters
|
|
2832
DHT Holdings
DHT
$3.8B
| $2.7M | ﹤0.01% |
250,098
-282,511
| -53% | -$3.11M |
2024 Q4
2 quarters
|
|
2833
BrandywineGLOBAL Dynamic US Large Cap Value ETF
DVAL
$64.6M
| $2.7M | ﹤0.01% |
190,944
+32,945
| +21% | +$441K |
2024 Q4
2 quarters
|
|
2834
Otter Tail
OTTR
$3.71B
| $2.7M | ﹤0.01% |
35,000
-1,957
| -5% | -$153K |
2024 Q4
2 quarters
|
|
2835
First Trust Small Cap Value AlphaDEX Fund
FYT
$182M
| $2.7M | ﹤0.01% |
53,485
-44,312
| -45% | -$2.13M |
2024 Q4
2 quarters
|
|
2836
Clearway Energy Class C
CWEN
$5.98B
| $2.69M | ﹤0.01% |
84,190
-30,771
| -27% | -$919K |
2024 Q4
2 quarters
|
|
2837
Amphastar Pharmaceuticals
AMPH
$1.08B
| $2.69M | ﹤0.01% |
117,119
+87,447
| +295% | +$2.17M |
2024 Q4
2 quarters
|
|
2838
Zeta Global
ZETA
$8.13B
| $2.69M | ﹤0.01% |
173,570
+49,889
| +40% | +$663K |
2024 Q4
2 quarters
|
|
2839
T. Rowe Price International Equity ETF
TOUS
$1.65B
| $2.69M | ﹤0.01% |
83,009
+58,819
| +243% | +$1.79M |
2025 Q1
1 quarter
|
|
2840
Invesco Russell 1000 Equal Weight ETF
EQAL
$796M
| $2.69M | ﹤0.01% |
54,554
-43,595
| -44% | -$2.04M |
2024 Q4
2 quarters
|
|
2841
Prospect Capital
PSEC
$1.09B
| $2.69M | ﹤0.01% |
844,465
+3,880
| +0.5% | +$13.5K |
2024 Q4
2 quarters
|
|
2842
Arrowhead Research
ARWR
$9.15B
| $2.68M | ﹤0.01% |
169,748
+132,039
| +350% | +$1.89M |
2024 Q4
2 quarters
|
|
2843
iShares GNMA Bond ETF
GNMA
$424M
| $2.68M | ﹤0.01% |
60,995
+21,977
| +56% | +$954K |
2024 Q4
2 quarters
|
|
2844
Lazard
LAZ
$3.55B
| $2.67M | ﹤0.01% |
55,709
-28,606
| -34% | -$1.2M |
2024 Q4
2 quarters
|
|
2845
Tandem Diabetes Care
TNDM
$1.15B
| $2.67M | ﹤0.01% |
143,274
-43,354
| -23% | -$859K |
2024 Q4
2 quarters
|
|
|
AIO
2846
Virtus Artificial Intelligence & Technology Opportunities Fund
AIO
$866M
| $2.67M | ﹤0.01% |
107,535
+8,776
| +9% | +$193K |
2024 Q4
2 quarters
|
|
|
EEX
2847
DELISTED
Emerald Holding
EEX
| $2.67M | ﹤0.01% |
549,506
-24,893
| -4% | -$108K |
2024 Q4
2 quarters
|
|
2848
Invesco S&P 500 BuyWrite ETF
PBP
$391M
| $2.66M | ﹤0.01% |
121,886
+7,281
| +6% | +$157K |
2024 Q4
2 quarters
|
|
|
OPRA
2849
Opera Ltd
OPRA
$1.57B
| $2.66M | ﹤0.01% |
140,958
+64,206
| +84% | +$1.1M |
2024 Q4
2 quarters
|
|
2850
FT Vest US Equity Deep Buffer ETF November
DNOV
$404M
| $2.66M | ﹤0.01% |
59,419
-308
| -0.5% | -$13.1K |
2024 Q4
2 quarters
|
|
Similar funds
Raymond James Financial's Q2 2025 Portfolio in Review
As of Q2 2025, Raymond James Financial held 7,081 positions worth $290B, up 9.4% from $266B the previous quarter. Its ten largest holdings account for 22% of the portfolio.
Raymond James Financial's Q2 2025 filing shows 2,183 new, 2,404 increased, 2,172 reduced and 80 closed positions. Its largest new stake was ServiceTitan Inc: 369,922 shares worth $39.6M. The largest sale was Merck, an estimated $636M.
By sector, the portfolio is most concentrated in Miscellaneous at 40% of assets, down from 40% a quarter earlier, followed by Technology and Financials.
- Raymond James Financial's largest Q2 2025 buy was ServiceTitan Inc: 369,922 shares worth $39.6M.
- Raymond James Financial added most to Vanguard S&P 500 ETF in Q2 2025, an estimated $962M increase.
- Raymond James Financial's biggest Q2 2025 reduction was Merck, cutting an estimated $636M.
- Raymond James Financial fully exited Discover Financial Services in Q2 2025, selling an estimated $36.8M.
- Raymond James Financial's ten largest holdings make up 22% of its $290B portfolio in Q2 2025.
- Raymond James Financial opened 2,183 new positions and closed 80 in Q2 2025.
- Raymond James Financial's portfolio value rose 9.4% quarter-over-quarter to $290B.
Based on Raymond James Financial's 13F filing for Q2 2025, filed 14 Aug 2025.